Why is homocysteine toxic for the nervous and immune systems?

Current Aging Science

Volumn 6, Issue 1, 2013, Pages 29-36

  Boldyrev, Alexander ^a,b   Bryushkova, Ekaterina ^a,b   Mashkina, Anna ^a   Vladychenskaya, Elizaveta ^a  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b RESEARCH CENTER OF NEUROLOGY   (Russian Federation)

Author keywords

Carnosine; Homocysteic acid; Homocysteine; Immune competent cells; Neurons; Nmda receptors

Indexed keywords

CALCIUM ION; CARNOSINE; CATECHOL METHYLTRANSFERASE INHIBITOR; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTAMATE RECEPTOR; HOMOCYSTEINE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; N ACETYLASPARTYLGLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

AMINO ACID BLOOD LEVEL; ARTICLE; BRAIN ISCHEMIA; CALCIUM CELL LEVEL; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CHRONIC BRAIN ISCHEMIA; CHRONIC DISEASE; DEGENERATIVE DISEASE; DRUG EFFECT; ERYTHROCYTE; EXCITOTOXICITY; HEART MUSCLE CELL; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNOCOMPETENT CELL; IMMUNOTOXICITY; LEARNING; LONG TERM EXPOSURE; MEMORY; NERVE CELL; NERVE CELL NECROSIS; NEUROTOXICITY; NEUTROPHIL; NONHUMAN; OSTEOBLAST; OXIDATIVE STRESS; PARKINSON DISEASE; PRENATAL PERIOD; PRIORITY JOURNAL; PROTECTION; RISK FACTOR; SPINAL CORD INJURY; T LYMPHOCYTE; UNIFIED PARKINSON DISEASE RATING SCALE;

ANIMALS; BRAIN ISCHEMIA; CARNOSINE; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; NEUROIMMUNOMODULATION; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PREGNANCY; RATS; REACTIVE OXYGEN SPECIES; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84882753116     PISSN: 18746098     EISSN: 18746128     Source Type: Journal    
DOI: 10.2174/18746098112059990007     Document Type: Article

References (56)

1. Thambyrajah J, Townend JN. Homocysteine and atherothrombosis -mechanisms for injury. Eur Heart 2002; 21: 967-4.
2. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J Am Med Assoc 1992; 268: 877-81.
3. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395-8.
4. Glushchenko AV, Jakobsen DW. Molecular targeting of proteins by L-homocysteine: mechanistic implications for vascular disease. Antioxid Redox Signal 2007; 9: 1883-98.
5. Tyagi N, Gillespie W, Vacek JC, Sen U, Tyagi SC, Lominadze D. Activation of GABA-A receptor ameliorates homocysteine-induced MMP-9 activation by ERK pathway. J Cell Physiol 2009; 220: 257-66.
6. Hasegawa T, Ukai W, Jo DG, et al. Homocysteic acid induced intraneuronal accumulation of neurotoxic Abeta42: implications for the pathogenesis of Alzheimer's disease. J Neurosci Res 2005; 80: 869-76.
7. Pacheco-Quinto J, Rodrigues de Turco EB, de Rosa S, et al. Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels. Neurobiol Dis 2006; 22: 651-6.
8. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-83.
9. van den Berg M, van der Knaap MS, Boers GH, Stehouwer CD, Rauwerda JA, Valk J. Hyperhomocysteinaemia (with reference to its neuroradiological aspects). Neuroradiology 1995; 37(5): 403-11.
10. Signorello MG, Pascale R, Leoncini G. Effect of homocysteine on arachidonic acid release in human platelets. Eur J Clin Invest 2002; 32(4): 279-84.
11. Upchurch GR Jr., Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272(27): 17007-12.
12. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002; 80(1): 101-10.
13. Kruman II, Kumaravel TS, Lohani A, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 2002; 22(5): 1752-62.
14. Gortz Ph, Hoinke A, Fleischer W, et al. Implications for hyperhomocysteinemia: not homocysteine but its oxidized forms strongly inhibit neuronal network activity. Neurol Sci 2004; 218: 109-14.
15. Boldyrev AA, Kazey VI, Leinsoo TA, et al. Rodent lymphocytes express functionally active glutamate receptors. Biochem Biophys Res Commun 2004; 324: 133-9.
16. Boldyrev AA. Homocysteinic acid causes oxidative stress in lymphocytes by potentiating toxic effect of NMDA. Bull Exp Biol Med 2005; 140(1): 33-7.
17. Ziemińska E, Stafiej A, Łazarewicz JW. Role of group I metabotropic glutamate receptors and NMDA receptors in homocysteine-evoked acute neurodegeneration of cultured cerebellar granule neurones. Neurochem Int 2003; 43: 481-92.
18. de Jong SC, van den Berg M, Rauwerda JA, Stehouwer CD. Hyperhomocysteinemia and atherothrombotic disease. Semin Thromb Hemost 1998; 24(4): 381-5.
19. Domagała TB, Undas A, Libura M, Szczeklik A. Pathogenesis of vascular disease in hyperhomocysteinaemia. J Cardiovasc Risk 1998; 5(4): 239-47.
20. Papatheodorou L, Weiss N. Vascular oxidant stress and inflammation in hyperhomocysteinemia. Antioxid Redox Signal 2007; 9: 1941-58.
21. Kim WK, Pae YS. Involvement of N-methyl-D-aspartate receptor and free radical in homocysteine-mediated toxicity on rat cerebellar granule cells in culture. Neurosci Lett 1996; 216(2): 117-20.
22. Makhro AV, Bulygina ER, Boldyrev AA. Effects of homocysteine and homocysteinic acid on cerebellar granule cells. Neurochem J 2007; 23(3): 179-84.
23. Boldyrev AA. Significance of reactive oxygen species for neuronal function. In: Tomasi A. Free Radicals, Nitric Oxide and Inflammation: Molecular, Biochemical, and Clinical Aspects. New-York: IOS Press. 2003; pp. 157-73.
24. Lipton SA, Kim WK, Choi YB, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-d-aspartate receptor. Proc Natl Acad Sci 1997; 94: 5923-8.
25. Poddar R, Paul S. Homocysteine-NMDA receptor-mediated activation of extracellular signal-regulated kinase leads to neuronal cell death. J Neurochem 2009; 110: 1095-06.
26. Rybakova Yu, Akkuratov E, Kulebyakin K, Brodskaya O, Dizhevskaya A, Boldyrev A. Receptor mediated oxidative stress in murine cerebellar neurons is accompanied by phosphorylation of MAP (ERK 1/2) kinase. Curr Aging Sci 2012; 5(3): 225-30.
27. Boldyrev AA. Molecular mechanisms of homocysteine toxicity. Biochemistry (Moscow) 2009; 74(6): 589-98.
28. Ganor Y, Besser M, Ben-Zakay N, Levite M. Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotact migration. J Immunol 2003; 170: 4362-72.
29. Pacheco R, Ciruela F, Casado V, et al. Group of metabotropic glutamate receptors mediates a dual role of glutamate in T cell activation. J Biol Chem 2004; 279: 33352-8.
30. Mashkina AP, Tyulina OV, Solovyova TI, et al. The excitotoxic effect of NMDA on human lymphocyte immune function. Neurochem Int 2007; 51: 356-60.
31. Tuneva EO, Bychkova ON, Boldyrev AA. Effect of NMDA on production of reactive oxygen species by human lymphocytes. Bull Exp Biol Med 2003; 136(2): 159-61.
32. Bryushkova EA, Stepanova MC, Boldyrev AA. Toxic effect of homocysteine on neutrophils is realised through NMDA-receptors. Biochemistry Moscow 2010, submitted.
33. Boldyrev AA, Carpenter DO, Johnson P. Emerging evidence for a similar role of glutamate receptors in the nervous and immune systems. J Neurochem 2005; 95(4): 913-8.
34. Boldyrev AA, Johnson P. Homocysteine and its derivatives as possible modulators of neuronal and non-neuronal cell glutamate receptors in Alzheimer's disease. J Alzheimer's Dis 2007; 11(2): 219-28.
35. Miglio G, Varsaldi F, Lombardi G. Human T lymphocytes express N-methyl-D-aspartate receptors functionally active in controlling T cell activation. Biochem Biophys Res Commun 2005; 338(4): 1875-83.
36. Mashkina AP, Cizkova D, Vanicky I, Boldyrev AA. NMDA receptors are expressed in lymphocytes activated both in vitro and in vivo. Cell Mol Neurobiol 2010; 30(6): 901-7.
37. Lodge PA, Sriram S. Regulation of microglial activation by TGFbeta, IL-10, and CSF-1. J Leukoc Biol 1996; 60(4): 502-08.
38. Arnold RS, Shi J, Murad E, et al. Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci USA 2001; 98(10): 5550-5.
39. Jackson SH, Devadas S, Kwon J, Pinto LA, Williams MS. T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation. Nat Immunol 2004; 5(8): 818-27.
40. Vladychenskaya EA, Tyulina OV, Urano S, Boldyrev AA. Effect of homocysteine and homocysteic acid on murine lymphocytes. Struct Funct Biochem 2010; submitted.
41. Zappacosta B, Mordente A, Persichilli S, Giardina B, de Sole P. Effect of homocysteine on polymorphonuclear leukocyte activity and luminol-dependent chemiluminescence. Luminescence 2000; 15: 257-60.
42. Boldyrev AA. Carnosine and oxidative stress in cells and tissues. Nova Sci Publ, New-York, Nova Sci Publishers Co, 2007.
43. Arzumanyan ES, Makhro AV, Tyulina OV, Boldyrev AA. Carnosine protects erythrocytes from the oxidative stress caused by homocysteic acid. Dokl Biochem Biophys 2008; 418: 44-6.
44. Bellia F, Calabrese V, Guarino F, et al. Carnosinase levels in aging brain: redox state induction and cellular stress response. Antioxid Redox Signal 2009; 11(11): 2759-5.
45. Pekcetin C, Kiray M, Ergur BU, et al. Carnosine attenuates oxidative stress and apoptosis in transient cerebral ischemia in rats. Acta Biol Hung 2009; 60(2): 137-48.
46. Baydas G, Koz ST, Tuzcu M, Nedzvetsky VS, Etem E. Effects of maternal hyperhomocysteinemia induced by high methionine diet on the learning and memory performance in offspring. Int J Dev Neurosci 2007; 25(3): 133-9.
47. Makhro AV, Mashkina AP, Solenaya OA, et al. Carnosine protects cells from oxidative stress induced by hyperhomocysteinemia. Neurochem J 2008; 2(3): 202-8.
48. Schroecksnadel K, Frick B, Wirleitner B, Winkler C, Schennach H, Fuchs D. Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol 2004; 5(1): 107-18.
49. Morris RG, Garrud P, Rawlins JN and O'Keefe J. Place navigation impaired in rats with hyppocampal lesions. Nature 1982; 297: 681-3.
50. Makhro AV, Mashkina AP, Solenaya OA, et al. Prenatal hyperhomocysteinemia as a model of oxidative stress of the brain. Bull Exp Biol Med 2008; 146(1): 33-5.
51. Fedorova TN, Belyaev MS, Trunova OA, Gnezditsky VV, Maximova MY, Boldyrev AA. Neuropeptide carnosine increases stability of lipoproteins and red blood cells as well as efficiency of immune competent system in patients with chronic discirculatory encephalopathy. Biol Membr 2008; 25(6): 458-62.
52. Boldyrev AA, Fedorova TN, Stvolinsky SL, Suslina ZA. Carnosine as a natural antioxidant and geroprotector: from molecular mechanisms to clinical trials. Rejuv Res 2009; 13: 156-8.
53. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002; 80(1): 101-10.
54. Youdim M, Geldenhuys W, van der Schyf C. Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease? Parkinsonism Relat Disord 2007; 13(3): 281-92.
55. Boldyrev A, Fedorova T, Stvolinsky S, et al. Carnosine increases efficiency of L-DOPA therapy of parkinsonics. Parkinsonism Rel Disord 2007; 13(S2): 99.
56. Boldyrev A, Fedorova T, Stepanova M, et al. Carnosine increases efficiency of DOPA therapy of Parkinson's disease: a pilot study. Rejuv Res 2008; 11(8): 821-7.